Moelis & Company - Q3 2024

Executive Summary

• Q3 2024 adjusted revenues were $280.7M (+1% YoY) and GAAP revenues were $273.8M, with diluted EPS of $0.22 GAAP and adjusted; sequential revenue increased from Q2’s $264.6M as M&A improved while non‑M&A was modestly softer.
• Compensation ratio accrued at ~75% and non‑comp expenses were $47.5M; management guided Q4 non‑comp expenses to be “similar” (~$48M), and reiterated comp leverage of 4–5 pts per $100M incremental revenues if activity accelerates.
• Product mix remained ~60% M&A / ~40% non‑M&A YTD, with Q3 also ~60/40; restructuring activity is expected to skew toward liability management, while capital markets benefited from strong private credit demand.
• Balance sheet stayed strong: cash and liquid investments rose to $297.7M with no debt or goodwill; MC declared a $0.60 quarterly dividend payable Dec 2, 2024 (record Nov 4).
• Catalysts: seasonality and healthy pipelines could support Q4 closing activity; improving sponsor engagement and an active private credit market are tailwinds, while regulatory execution timelines and LP fundraising cadence remain pacing risks.

What Went Well and What Went Wrong

• What Went Well

  • M&A revenues increased; YTD mix ~60% M&A / 40% non‑M&A with Q3 at ~60/40, reflecting gradual improvement and strong public strategic activity earlier in the year.
  • Private credit tailwinds: capital markets had its best quarter since Q1 2022; hybrid capital demand and disintermediation from banks created advisory opportunity for bespoke financing solutions.
  • Strong balance sheet and capital return maintained: cash and liquid investments $297.7M; quarterly dividend of $0.60 declared; “no debt or goodwill” supports resilience.
  • Quote: “We are well positioned to drive long‑term growth” — Ken Moelis, CEO.

• What Went Wrong

  • Non‑M&A revenues modestly declined YoY in Q3, partially offsetting M&A increases; longer transaction completion cycles persisted vs a full bull market.
  • Compensation ratio stayed elevated at ~75% for Q3 amid staffing needs to service elongated backlogs; headcount up YoY and MD count decreased sequentially, adding cost friction near‑term.
  • Regulatory and investment committee processes continue to slow closings; management flagged antitrust scrutiny and LP fundraising cadence as bottlenecks.

Transcript

Operator (participant)

Good afternoon, and welcome to the Moelis & Company Earnings Conference Call for the Third Quarter of 2024. To begin, I'll turn the call over to Mr. Matt Tsukroff.

Matt Tsukroff (Head of Investor Relations)

Good afternoon, and thank you for joining us for Moelis & Company's Third Quarter 2024 financial results conference call. On the phone today are Ken Moelis, Chairman and CEO, and Joe Simon, Chief Financial Officer. Before we begin, I would like to note that the remarks made on this call may contain certain forward-looking statements, which are subject to various risks and uncertainties, including those identified from time to time in the Risk Factors section of Moelis & Company's filings with the SEC. Actual results could differ materially from those currently anticipated. The firm undertakes no obligation to update any forward-looking statements. Our comments today include references to certain adjusted financial measures. We believe these measures, when presented together with comparable GAAP measures, are useful to investors to compare our results across several periods and to better understand our operating results.

The reconciliation of these adjusted financial measures with the relevant GAAP financial information and other information required by Reg G is provided in the firm's earnings release, which can be found on our investor relations website at investors.moelis.com. I'll now turn the call over to Joe to discuss our results.

Joe Simon (CFO)

Thanks, Matt. Good afternoon, everyone. On today's call, I'll go through our financial results, and then Ken will comment further on the business. We reported $281 million of adjusted revenues in the third quarter. Our adjusted revenues for the first nine months were $763 million, up 18% from the prior year period. The year-over-year increase in revenues for the first nine months of the year is driven by growth across all major product areas, and our year-to-date revenue distribution remains approximately 60% M&A, 40% non-M&A. Moving to expenses, our third quarter compensation expense was accrued at 75%, consistent with the first two quarters. Our non-compensation expenses in the third quarter were $48 million, and we expect a similar non-comp expense result in quarter four. Moving to taxes, our underlying corporate tax rate was 34%, consistent with the prior quarter.

Regarding capital allocation, the board declared a regular quarterly dividend of $0.60 per share, consistent with the prior period. And lastly, we continue to maintain a strong balance sheet with $298 million of cash and no debt. And I'll now turn the call over to Ken.

Ken Moelis (Chairman and CEO)

Thanks, Joe, and good afternoon, everyone. We've seen gradual improvement in the M&A market throughout the year. Equity market valuations are at or near all-time highs. The Fed has changed course and appears to be committed to lower interest rates, although the pace may be up for debate. At the same time, rapid innovation driven by technology fuels the need for M&A, and these factors suggest we are getting closer to the next upcycle in M&A. In our capital structure advisory business, we continue to experience elevated activity and engagement with clients. We anticipate a prolonged restructuring cycle centered around liability management exercises due to a large amount of non-investment grade debt maturing in the next few years. Turning to capital markets, the rise of private credit has allowed us to compete with the legacy banks on arranging capital for our clients.

This market actually appears to be larger and developing more rapidly than we had anticipated. We were early to identify, and we have invested in this secular trend. We continue to experience strong demand for structured capital solutions as issuers look to grow their businesses or to refinance upcoming maturities. Turning to talent, we really recently added a biotech MD who's set to join the firm next month. Our recruiting efforts remain active, and we will continue to selectively add talent in areas of key strategic importance to the firm. Our expertise across products, sectors, and regions has deepened, allowing us to deliver even more impactful, independent, and conflict-free advice. We are well-positioned to drive long-term growth. And with that, I'll open it up for questions.

Operator (participant)

At this time, I would like to remind everyone in order to ask a question, please press star, then the number one on your telephone keypad. Your first question comes from the line of Devin Ryan with Citizens JMP. Your line is now open.

Devin Ryan (Analyst)

Thanks. Hi, Ken. Hi, Joe. First question, just on comp ratio, kind of near term and then intermediate term. Your revenue is up 18% year to date. I think comp expense is up about 7%. So you're already seeing some leverage there, but you know, obviously, backlogs appear to be building. So just love to get some sense around whether you feel like there might be some positive leverage in the fourth quarter off of this 75% level, and then how we should think about that relationship into 2025. Should we still think about kind of that guide that you guys had been previously given?

You know, every hundred million or so is four to five points, just how we should think about that connection as we look into 2025 and beyond. Thanks.

Ken Moelis (Chairman and CEO)

I'm gonna ask Joe to reiterate, 'cause I think we think the model that we gave you, that kind of algorithm works, and your question about the fourth quarter is, yes, dependent on the fourth quarter revenue. This market continues to show signs of, you know, having energy behind it and having a desire. Again, I've said this, I think two or three calls now, but our pipelines continue to be at all-time highs. Our announced transactions are at all-time highs. The amount of activity is very significant, and yet the time to complete the transactions continues to be longer than you'd see, you know, in a full-scale bull market.

So I just don't think we've seen the increase in the speed to market that we might have thought we saw when the Fed first started to move rates. So yes, the answer is there is leverage, and I hope the fourth quarter continues on the pace of improvement that we've seen. I think I'll turn it over to Joe for a second, but I think the algorithm he gave you on four to five points per hundred million is still holds true.

Joe Simon (CFO)

Yeah, I think that's right. It does, barring any significant hiring phase, which we don't expect at this time. So I think that the algorithm is still relevant.

Devin Ryan (Analyst)

Okay, great. That's, that's helpful, and then, just a follow-up, Ken, just on the interplay M&A with interest rates. So obviously, we've been talking about rates coming down as a catalyst, but, you know, we just had one move, right? And it was recent, and we're still pretty far away from, I think, what many people consider a neutral rate. So, in terms of sponsor reengagement, you know, do you think we need to kinda see where rates settle out to really see reacceleration? Or is this just, you know, the rates coming down, people see the writing, and so they're starting to, you know, try to progress things with the expectation that by the time you're actually getting to closing a deal, rates will maybe be closer to that neutral rate?

I'm just curious kinda how that interplay is working out based on the first move we've seen.

Ken Moelis (Chairman and CEO)

A lot of that question, Devin, anticipates that, you know, I know exactly what the neutral rate is or the Fed does or anybody does. Interestingly, the ten-year probably disagrees with you and has moved in the other direction. Maybe that's causing some of the slowdown. But I think it's the whole system will move together. We find that the sponsors are engaged. It's very different than it was, I'd say, eighteen months ago, when the default was everybody knew you weren't gonna do anything. It was kinda like waiting for Godot, waiting for something to happen. We are in active conversations in and around all sorts of things: liability management, private credit placement, M&A. There's a lot of things going on.

I still think one of the missing ingredients is, and we were talking about this the other day, there's a lot of partners, sector partners in private equity and other sponsors placing sponsors like that, that are out there on their front foot, getting long ideas and maybe even transactions. Then I think it gets back to the investment committee, and maybe it's the slowness of the replacement capital, you know, the replacement LP capital. So the whole system hasn't really started back up, where everybody knows they can go back out and raise another fund. I think somewhere between the partner on the transaction itself and the entity as a firm at investment committee decides where they're gonna allocate capital, things just seem to slow down a little bit.

And, you know, the exact opposite happens in a bull market. In 2021, things just accelerated right through to completion. So, it can be, you know, maybe if interest rates, if the Fed continues to cut, that will restart the whole process, but it's kind of a whole system that will move together, I think.

Devin Ryan (Analyst)

Okay. That's great. Thanks, Ken. Appreciate it.

Operator (participant)

Your next question comes from the line of Ken Worthington with J.P. Morgan. Your line is now open.

Ken Worthington (Analyst)

Hi, good afternoon. This is sort of a pie-in-the-sky question as well. If you go back to the beginning of the year, Ken, you were optimistic about the outlook for M&A. You're still optimistic about the outlook for M&A. At the beginning of the year, you know, mentioned that Moelis' pipeline was at, you know, record levels. We're still at record levels. The S&P is, you know, at sort of record highs. But M&A, the recovery has been fine so far. You called it gradual. If there are no surprises, so nothing out of left field, so to speak, you know, could 2025 just be another kind of so-so year? You know, better than 2024, but maybe disappointing relative to high expectations.

And if we have our chat, you know, a year from now and activity was so-so rather than great, you know, what are the likely drivers of expectations that... a reality that falls short of expectations next year? Is it just rates? You mentioned that a lot of things are working together. You know, what else sort of comes to mind, on what could, you know, drive a mediocre rather than, like, a really healthy recovery and activity levels next year?

Ken Moelis (Chairman and CEO)

Again, a good question. So I'm gonna repeat what I was trying to say. Maybe I got too, too involved. I think everything about it, barring an unseen, you know, external event, twenty-five, as you said, I think it'll be a good year. It'll be somewhere between good and very good. It, the activity levels are picking up. It is different than it was if you went back, you know, a year ago. I don't think we were quite at the levels we were of activity, of optimism, of people on their front foot. If I had to say one big thing, I think the thing that's gonna... and it might be a derivative of interest rates, but it's the ability to raise capital in the LP market.

Is there, is there a fund, you know, 10 behind fund nine that is available if you allocate capital and, you know, and use up your last 25% of capital? That may not be. That may be related to interest rates, and so, you know, I'm not discounting interest rates. It may be related to a lot of things. 'Cause I think the rise in interest rates definitely stopped that allocation of capital going into at least private equity alternatives. A lot of capital is going into private credit alternatives.

But if I had a thermometer, and you could tell me how that market looked, how the reallocation of capital into the private equity market looked, that might be a derivative I said of interest rates, but it would probably be the best indicator of whether we'll have a mediocre recovery or a very good recovery.

Ken Worthington (Analyst)

Okay. Okay. Well, it's pie in the sky. I appreciate your thoughts. Thanks. Thanks much.

Ken Moelis (Chairman and CEO)

Thanks.

Operator (participant)

The next question comes from the line of Brennan Hawken with UBS. Your line is now open.

Brennan Hawken (Analyst)

Good evening. How you doing, Ken?

Ken Moelis (Chairman and CEO)

Good.

Brennan Hawken (Analyst)

So it's a bit of an unusual environment, for sure, but, you know, as we're thinking about the coming quarter, do you expect that we'll be seeing the typical seasonality and a stronger fourth quarter than what we've been seeing here year to date? Is the seasonality, you think, still something we can count on?

Ken Moelis (Chairman and CEO)

You know, again, I don't want to guide, but yes, the business seems to feel, and I'm not sure it's totally about the seasonality as much as it. Yeah, there'll be some deals that always try to close in the fourth, so that's the little bit of seasonality as people rush to close at year-end. But the business also seems to be gradually getting better each quarter, somewhere between, you know, a gradual or mediocre recovery every quarter. And that could change. By the way, we're gonna have an event here in a couple of weeks, elections. I think what Powell does after that, there's a lot of things that could accelerate that. So it feels like things are improving, let's put it that way. I'm not gonna try to guide to a number. And then I think there are things that could accelerate that.

Brennan Hawken (Analyst)

Okay. Yeah, wasn't trying to fish for a number, but thanks for that, the high-level commentary. So if we end up seeing some seasonality then, and the leverage, as Joe just endorsed earlier on the call, you know, and we have a decent fourth quarter here, you know, it sounds as though you're implying that the 75% comp ratio that we saw in the first nine months, that's not necessarily the way we're gonna shake out for the year, and we have to see how solid the fourth quarter can end up being before we can make that call. Is that fair?

Ken Moelis (Chairman and CEO)

Yes. Yeah, we, what we look at is what does the run rate as of today get based on this market indicate? And I think that's the conservative way to think about it. If the market gets better, then the comp ratio will get better.

Brennan Hawken (Analyst)

Excellent. Thanks for taking my questions.

Ken Moelis (Chairman and CEO)

Thank you.

Operator (participant)

Your next question comes from the line of Brendan O'Brien with Wolfe Research. Your line is now open.

Brendan O'Brien (Analyst)

Good evening, and thanks for taking my questions. I guess to start, I just wanted to talk about headcount. While your MD count is down slightly year on year, your employee count is up nearly 20%, with a fairly significant increase quarter on quarter, in 3Q. I just wanted to get a sense as to what drove the big step up in headcount. Is it simply because you need to fill out some of the teams after the significant recruiting done over the past few years, or, you know, something else?

Ken Moelis (Chairman and CEO)

It's a little bit of both. I think we're a little overstaffed per MD. We believe our ratio is a little overstaffed per MD, but I will say some of that is there are some sectors where we are recruiting in senior talent, where we have junior talent that we like as well, and that might distort it just a little bit, that we kept some teams pending. I think we announced we just said we're gonna hire a senior biotech banker. There, those types of ratios might end up as a result of having a team that we think is capable of calling on it, but they're not MDs yet, and we're gonna bring in an MD on top of that.

And some of it is just, again, part of the comp ratio, and I think I've said this before, is as deals take longer and your backlog kinda stays there, you don't abandon your backlog. You sorta have all the deals that you thought you were gonna do six months ago, and you still have all the deals that you wanna execute on in the next six months. And so I think some of this drawing out of the pipeline and the backlog and even the length of time it gets to take deals done end up you end up with a larger headcount just because you can't walk away from them. You can't just leave them on the shelf. It's not a commodity.

You have to service the client whose transaction you took on eighteen months ago but has not completed. And that's what happens as the pipeline gets dragged out.

Joe Simon (CFO)

Yeah, and just one correction, Brennan. I'm not sure what figure you're looking at, but year to date, I think we're closer to 12%, not 20%.

Brendan O'Brien (Analyst)

I was looking at year on year, Joe.

Joe Simon (CFO)

Okay.

Brendan O'Brien (Analyst)

'Cause I wasn't sure if there was some seasonality in terms of, like, summer hiring and the like, but, yeah, no, that all makes sense, Ken. I guess for my follow-up, I just wanted to touch on capital allocation, and specifically, whether you would consider doing an acquisition to accelerate growth. I know it's something that you've not been interested in previously, but given where you and your peers are trading today, it feels like there could be some interesting opportunities out there to leverage your multiple, to do some accretive acquisitions and accelerate growth. So just wanted to get a sense as to how your thinking has evolved here, if at all.

Ken Moelis (Chairman and CEO)

... I'm not, I've never been 100% against acquisitions. I just, you know, there's never gonna be- I don't see a way that a large M&A deal happens, by the way. Again, I'm a function of where you've grown up in the world. I was at DLJ when Credit Suisse merged. I don't think I could ever do a transaction of that, you know, magnitude. But, you know, what we did with SVB, in my mind, was as close to an acquisition as you could get. We took 50 bankers out without doing an acquisition. So I think there is that type of a situation where you might have to accomplish it through, as you said, a purchase. I'm not averse to that.

If it makes sense, if we're, if it's the right price, if it's the right culture. You know, I think they're very difficult to do. I think the earn-out method of buying those comes with risks. They don't show up for five years. I know that can make your financials look good, but I think at the end of five years and when earn-outs run out, I've seen what can happen. So again, I'm not averse to. You know, I'm not saying I won't do it, but it would look and feel much more like an SVB type of thing than it would anything dramatic.

Brendan O'Brien (Analyst)

That's great color. Thank you, guys, for taking my questions.

Operator (participant)

Your next question comes from the line of Mike Brown with Wells Fargo Securities. Your line is now open.

Mike Brown (Analyst)

Hi, good afternoon. Ken, I just wanted to maybe follow up on the, on the comp ratio discussion. How is the competitive landscape in terms of hiring? Are you finding that the fight for talent is getting tougher and resulting in a need to pay up? And are you also finding a need to pay up to retain your talent? I guess I'm just trying to figure out if there's potentially some more, you know, structural pressure on the comp costs as we start to think more about 2025. And of course, I appreciate the comp ratio algorithm that you guys have laid out, but just trying to think about that dynamic right now.

Ken Moelis (Chairman and CEO)

I'd say it feels fairly stable. Over the last really eighteen months, I think there are people available. You know, I think the market has quieted down a little, but as in all markets, there's always gonna be 5-10% of people who wanna move for whatever reasons. I think the large banks continue, especially with this pressure on what I call, you know, as, again, this disintermediation of lending from the bank and going to private credit. I think the regulators have and are intent on pushing a risky credit off of the major bank's balance sheet and into the private credit market. I think that's what's driving that market.

And as a result, I think bankers who would tend to have gone to those banks in order to be able to provide, you know, I call it off-market credit or better credit, are gonna become more and more available. But I think it's been stable. I mean, it's hard to say overall, if you go for certain segments and there's a, you know, a shortage in that segment, you could find some pressure. But I think talent's available, and it's stayed about. Look, the market's been pretty flat. I think the cost of acquisition has been pretty flat for eighteen months.

Mike Brown (Analyst)

Okay, great. Thanks for all that color. Let's just change gears and talk about restructuring. How has activity been holding up there? And when we think about the next eighteen months, how do you expect restructuring activity to progress? And what will be kind of the interplay between, call it, traditional restructuring and liability management?

Ken Moelis (Chairman and CEO)

I think it'll be more liability management than restructuring because the capital markets are overly open. Really, the Chapter 11 part of financial restructuring usually happens when, you know, you get to a maturity and there's no other alternative. Chapter 11 is always the last alternative. That kind of a full-scale restructuring is last, you know, the last alternative, and today there is aggressive money, there's risk-oriented money, there's a lot of capital that will find a way to play in a capitalization and extend maturity. There's also, again, the liability management exercises we do now are pretty sophisticated. The large institutions are willing to participate, and do the analysis, and if the company has a valid business, usually provide runway. So, you know, I think that will be the dominant, the dominant part of what we call restructuring.

And I think it's gonna be gradual and continuous because the size of the credit market just has gotten so much bigger over the last seven or eight years. And it's you can almost do a regression, and it's the amount of restructuring or liability management you have is a direct correlative event to how much issuance happened, you know, somewhere between two to four years before the event. There's just gonna be a percentage of issues, and if the market's growing, the liability management market will continue to grow.

Mike Brown (Analyst)

Okay. Thank you, Ken. Appreciate the call.

Operator (participant)

Your next question comes from the line of Aidan Hall with KBW. Your line is now open.

Aidan Hall (Analyst)

... Great. Thanks for taking my questions. Ken, maybe just to follow up on your M&A comments or, you know, large team lift outs. Curious how you would characterize appetite for not just, like, traditional M&A bankers, but maybe some of the non-M&A capabilities? You know, obviously, private capital advisory, primary fundraising as well, are areas that come to mind that some of your competitors have been a little more aggressive in kind of growing. So any appetite there, or do you guys have ambitions to grow in those verticals?

Ken Moelis (Chairman and CEO)

Yes. The answer is yes, and yes. We have significant ambitions to be in there. We think it's an important part. One of the things we want to be is the most valuable and important provider of services to the private equity community and, well, and alternative private credit as well. So we're looking at that, and, yeah, if that were, that would be on the order of something that I think would look and feel like an, you know, almost an SVB. When I use that, it's just of a size that, but of a size and shape that if it were something that made sense for us, might make sense in M&A, as well as hiring talent, either way.

Aidan Hall (Analyst)

Got it. Appreciate, appreciate the color there. And maybe just a follow-up on Brennan's question about kind of the headcount more on a sequential basis. It looks like the MD headcount decreased by five quarter over quarter. Anything to call out there? It just seems pretty elevated, but I know there can be some noise here and clarifications. So I just want to clarify.

Ken Moelis (Chairman and CEO)

Yeah. I think what happens is, as you know, those might have occurred four, five, six months ago. Some that are voluntary or, you know, we might give people time. There's also garden leave if somebody were to leave. So yeah, I think those are a result of things that might have happened in and around bonus time or after, right around that time, where I'm not saying they're all managed, but we manage our headcount. Some of them are not, you know, on our things that we provoked, but I do think that's what happens. It takes time, sometimes four, five, six months for an exit to show up in your headcount.

Aidan Hall (Analyst)

Got it. Appreciate it. Thank you for taking my questions.

Operator (participant)

Again, just as a reminder, if you would like to ask a question, please press star then the number one on your telephone keypad. The next question comes from the line of Ryan Kenny with Morgan Stanley. Your line is now open.

Ryan Kenny (Analyst)

Hi, thanks for taking my question. Just on the comments around longer lag to complete transactions, can you just give us an update on what's still driving that? Is it all regulatory-driven? Is it just a longer vetting process? And do you expect that lag to normalize as the cycle picks up and sponsors start coming back and forth?

Ken Moelis (Chairman and CEO)

It can be all the above. I think in the public markets, it can be some regulatory. In the private markets, it's usually not regulatory in private equity. But I do think, again, you know, these dynamics are kind of interesting. You have these large organizations and sector partners go out, and we might have a product that is attractive to them. You might go through a long process in which, you know, you're getting close to having a transaction. Well, when it gets coordinated inside the larger entity, the investment committee of that entity, it might not be the right time for their capital, for their fundraise needs, for their exit needs.

There's. I think there's a lot of dynamics going on around positioning private equity and trying to figure out how much capital do we have in fund one? When do we want or fund five, whatever fund you're in. When do we want to go to market? I think in 2020 and 2021, again, I use those markets because they were kind of the epitome of a bull market. The answer was, we can complete that transaction, and the sooner the better, because if we want to go back to market and raise another fund, everybody's waiting for it, and we already have commitments, and things will roll. The fundraising market has been very slow. It's. That's been...

If you think M&A has been painful, I think the act of fundraising in the private equity market was extremely slow in 2023, getting a little better in 2024, and people are hoping for a brighter 2025. But I also think the inability to project that and feel confident about that slows everybody down in the process. I think it's just one of those things that you know is lurking behind the scenes as part of the slowdown. And so, and by the way, it's not always when you have a deal. Look, there are bake-offs we've done, been assigned a project and done the diligence, gotten to work on it, and then it was put on hold for six months. That happens too. So it's not all regulatory, it's not all market, it's not all interest rates.

It's a whole bunch of things that just come together when markets are, you know, rockier or do not seem to be. Interest rates do not seem to be going rapidly in one direction, and definitely the funding from private sources does not seem to be going directly in one direction. So I think it's all of the above.

Ryan Kenny (Analyst)

... All right, helpful. And then one technical question. On the $7 million gain on Moelis Australia shares, was that a one-off? And any update on how Australia fits into your strategy from here?

Ken Moelis (Chairman and CEO)

Australia has been. You know, when we started with Australia, it was purely advisory, and we wanted to do advice with them. They have been very entrepreneurial, and they created a pretty significant public company down there called MA Financial now. That was a reverse inquiry. They called us up. They went public, I think, four years ago or something. They called us up and said, "We have a buyer for five million shares," and we just decided, why not take the liquidity and do it? It was helpful to them, and I think it was helpful to us. We continue to do things with them. We continue to use them and co-advise on anything that happens in Australia. It's a significant alliance for us, and we have no plans on any of the other stocks.

That happened to be reverse inquiry, so we executed.

Ryan Kenny (Analyst)

Thank you.

Operator (participant)

The last question comes from the line of James Yaro with Goldman Sachs. Your line is now open.

James Yaro (Analyst)

Good afternoon. I think we've seen a couple of recent successful sponsor IPOs. Is that something that's starting to come up in your dialogues with private equity? And do you think that's, you know, something that could lead to more activity, either in ECM or M&A in that part of the market?

Ken Moelis (Chairman and CEO)

I think there'll be more sponsor IPOs. Some of the transactions are large enough that finding an exit buyer is difficult. They're, you know, very successful. Large buyouts end up having even larger exits. The IPO market, I think, is an obvious place for them to go. Look, again, with the stock market at all-time highs and interest rates coming down, you'd expect to see an IPO market develop. It's actually kind of strange. Nasdaq's at an all-time high, so it's kind of strange that there is no IPO market. I think if people come to market with the right price, with quality product, that there will be an IPO market, and people will take advantage of it.

James Yaro (Analyst)

Okay, thanks. Just a quick one here. Maybe if any way you could just size the percentage contribution to revenue this quarter from restructuring capital markets versus M&A?

Ken Moelis (Chairman and CEO)

Yeah, I think M&A was about sixty, and all the other was about 40. So that's been pretty consistent throughout the year.

James Yaro (Analyst)

Okay, that's really helpful. Thanks a lot.

Operator (participant)

At this time, there are no further questions, and I would like to turn it back over to Mr. Ken Moelis. Please go ahead.

Ken Moelis (Chairman and CEO)

Thank you very much. Appreciate it. Look forward to talking to you after the end of the year.

Operator (participant)

This concludes today's conference call. You may now disconnect.